Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2016 Apr;14(4):389-400.
doi: 10.6004/jnccn.2016.0046.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016

Kenneth C Anderson  1 , Melissa Alsina  2 , Djordje Atanackovic  3 , J Sybil Biermann  4 , Jason C Chandler  5 , Caitlin Costello  6 , Benjamin Djulbegovic  2 , Henry C Fung  7 , Cristina Gasparetto  8 , Kelly Godby  9 , Craig Hofmeister  10 , Leona Holmberg  11 , Sarah Holstein  12 , Carol Ann Huff  13 , Adetola Kassim  14 , Amrita Y Krishnan  15 , Shaji K Kumar  16 , Michaela Liedtke  17 , Matthew Lunning  18 , Noopur Raje  19 , Frederic J Reu  20 , Seema Singhal  21 , George Somlo  15 , Keith Stockerl-Goldstein  22 , Steven P Treon  1 , Donna Weber  23 , Joachim Yahalom  24 , Dorothy A Shead  25 , Rashmi Kumar  25
Affiliations
Practice Guideline

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016

Kenneth C Anderson et al. J Natl Compr Canc Netw. 2016 Apr.

Abstract

These NCCN Guidelines Insights highlight the important updates/changes specific to the 2016 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. These changes include updated recommendations to the overall management of multiple myeloma from diagnosis and staging to new treatment options.

PubMed Disclaimer

Figures

MYEL-A
MYEL-A
STAGING SYSTEMS FOR MULTIPLE MYELOMA1
MYEL-B
MYEL-B
DEFINITION OF MULTIPLE MYELOMA (SMOLDERING AND ACTIVE)
MYEL-D
MYEL-D
MYELOMA THERAPY1–4 MYELOMA THERAPY1–4,9
MYEL-D
MYEL-D
MYELOMA THERAPY1–4 MYELOMA THERAPY1–4,9
See this image and copyright information in PMC

Similar articles

  • NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.
    Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA. Kumar SK, et al. J Natl Compr Canc Netw. 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002. J Natl Compr Canc Netw. 2018. PMID: 29295877
  • NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.
    Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Liedtke M, Martin T, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, Kumar SK. Callander NS, et al. J Natl Compr Canc Netw. 2022 Jan;20(1):8-19. doi: 10.6004/jnccn.2022.0002. J Natl Compr Canc Netw. 2022. PMID: 34991075
  • NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.
    Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Costello C, D'Angelo C, Derman B, Devarakonda S, Elsedawy N, Godara A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Vogl D, Kovach E, Kumar R. Kumar SK, et al. J Natl Compr Canc Netw. 2025 May;23(5):132-140. doi: 10.6004/jnccn.2025.0023. J Natl Compr Canc Netw. 2025. PMID: 40340857
  • Multiple Myeloma Guidelines and Their Recent Updates: Implications for Imaging.
    Mosebach J, Thierjung H, Schlemmer HP, Delorme S. Mosebach J, et al. Rofo. 2019 Nov;191(11):998-1009. doi: 10.1055/a-0897-3966. Epub 2019 May 28. Rofo. 2019. PMID: 31137045 Review. English, German.
  • NCCN: Multiple myeloma.
    Traynor AE, Noga SJ; NCCN Multiple Myeloma Practice Guidelines Panel. Traynor AE, et al. Cancer Control. 2001 Nov-Dec;8(6 Suppl 2):78-87. Cancer Control. 2001. PMID: 11760563 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. - PubMed
    1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–548. - PubMed
    1. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–3420. - PubMed
    1. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–854. - PubMed
    1. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–2869. - PMC - PubMed

Publication types